多索茶碱治疗慢性阻塞性肺疾病急性加重期患者的临床疗效

Clinical Efficacy of Doxofylline in the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨多索茶碱治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法选取2017年9月~2018年8月我院收治的COPD急性加重期患者50例,随机分为观察组及对照组,各25例。对照组给予患者吸氧、抗感染、化痰及解痉平喘等治疗,观察组在对照组基础上加用多索茶碱0.3g静滴治疗,比较两组动脉血气、CAT评分、临床疗效有效率。结果治疗后,两组pH比较,差异无统计学意义(P>0.05);观察组PaO2高于对照组,PaCO2低于对照组,差异有统计学意义(P<0.05)。观察组CAT评分低于对照组[(17.68±2.77)分vs(19.76±2.60)分],差异有统计学意义(P<0.05)。观察组总有效率为88.00%,高于对照组的76.00%,差异有统计学意义(P<0.05)。结论多索茶碱治疗COPD急性加重期患者的临床治疗效果较好,患者的各项症状均得到缓解,值得临床使用。

Objective To investigate the clinical efficacy of doxofylline in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 50 patients with acute exacerbations of COPD admitted to our hospital from September 2017 to August 2018 were randomly divided into observation group and control group, 25 cases each. The control group was given oxygen, anti-infection, phlegm and antispasmodic and antiasthmatic treatment. The observation group was treated with doxofylline 0.3 g intravenously on the basis of the control group. The arterial blood gas, CAT score and clinical efficacy were compared between the two groups.Results After treatment, there was no significant difference in pH between the two groups (P>0.05). PaO2 in the observation group was higher than that in the control group, and PaCO2 was lower than the control group, the difference was statistically significant (P<0.05). The CAT score of the observation group was lower than that of the control group [(17.68±2.77) points vs (19.76±2.60) points],the difference was statistically significant (P<0.05).The total effective rate of the observation group was 88.00%, which was higher than that of the control group 76.00%,the difference was statistically significant(P<0.05).Conclusion Doxofylline is effective in the treatment of patients with acute exacerbation of COPD. All have been alleviated and worthy of clinical use.